Investigating CCRL2's role in myelodysplastic syndrome
Official title: CCRL2 as a Regulator of Growth and Novel Target in Myelodysplastic Syndrome
Funded at Johns Hopkins University · NIH-11076301 · Data updated 2026-11-12
This study is looking at how a specific gene called CCRL2 affects the growth of harmful cells in myelodysplastic syndrome (MDS), especially in men, to find new ways to improve treatment for people with this blood disorder.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | April 25, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $171,720 |
| NIH project number | 5K08HL168777-03 |
| Project ID | NIH-11076301 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with high-risk myelodysplastic syndrome, particularly those who have not responded well to current treatments.
✕Less likely to help
Patients with low-risk myelodysplastic syndrome or those without a confirmed diagnosis may not benefit from this research.
What this research studies
This research focuses on understanding how the CCRL2 gene influences the growth of malignant cells in myelodysplastic syndrome (MDS), a serious blood disorder. The study aims to identify the mechanisms by which CCRL2 contributes to the survival and proliferation of these harmful cells, particularly in men who are affected more severely than women. By exploring the interactions between CCRL2 and other cellular components, the research seeks to uncover potential therapeutic targets that could improve treatment outcomes for patients with MDS.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and quality of life for patients with myelodysplastic syndrome.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in blood disorders, suggesting that this approach could be effective.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Karantanos, Theodoros — Johns Hopkins University
- Study coordinator: Karantanos, Theodoros
Related research
Other NIH-funded projects on the same topics.
-
Targeting diverse stem cells in myelodysplastic syndrome to eradicate the disease
Aimed at identifying weaknesses in the diverse stem cell populations of myelodysplastic syndrome so future treatments can wipe out the root cause of the disease.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
-
Targeting metabolic weak spots in myelodysplastic syndrome stem cells
The team is trying metabolism-based treatments to kill the stem cells that drive high-risk myelodysplastic syndrome (MDS).
-
Investigating the role of PI3 kinase in Myelodysplastic Syndrome
This study is looking at how certain changes in genes might affect blood cell production in older adults with Myelodysplastic Syndrome (MDS), and it hopes to find new ways to help improve treatment for people with this condition.
-
Identifying harmful and harmless genetic variations in blood cancer predisposition genes
This study is looking at how certain changes in a gene called DDX41 might affect the chances of developing blood disorders like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), so that doctors can provide better advice and support for patients at risk.
-
Understanding how immune evasion occurs in high-risk myelodysplastic syndrome
This study is looking at how a protein called VISTA helps high-risk myelodysplastic syndrome (HR-MDS) avoid being attacked by the immune system, with the goal of finding new ways to improve treatments for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.